Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer

Yingqiu Xie; Haiyan Fan; Wenfu Lu; Qing Yang; Ayan Nurkesh; Tleubek Yeleussizov; Aisulu Maipas; Jiang Lu; Limara Manarbek; Zhenbang Chen; Enrico Benassi

doi:10.1038/s41388-018-0608-2

Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer

Yingqiu Xie
, Haiyan Fan
, Wenfu Lu
, Qing Yang
, Ayan Nurkesh
, Tleubek Yeleussizov
, Aisulu Maipas
, Jiang Lu
, Limara Manarbek
, Zhenbang Chen
, Enrico Benassi

Nazarbayev University
Meharry Medical College
Shenzhen University

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.

Original language	English
Pages (from-to)	2967-2983
Number of pages	17
Journal	Oncogene
Volume	38
Issue number	16
DOIs	https://doi.org/10.1038/s41388-018-0608-2
Publication status	Published - Apr 18 2019

Funding

Acknowledgements We would like to thank Drs. Simon W. Hayward and LaMonica Stewart for cell lines, Lynn M. Matrisian for providing MMP7-Luc plasmid. This work was supported in part by NIH grants MD004038, MD007586, CA091408 and CA163069, UL1 RR024975-01 and UL1 TR000445-06. IF and IHC analysis was performed by Meharry Medical College Morphology Core, which is supported in part by NIH grants U54 MD007593, G12 MD007586, R24 DA036420, and S10RR0254970. We would like to thank Dr. Guo-liang Li, Zhanna Alexeyeva, Aigerim Kabulova, Zhibek Keneskha-nova, Akerke Altaikyzy for the kind help or assistant on research. Quantum mechanical calculations were performed on the clusters of the Siberian Supercomputer Center (http://www2.sscc.ru) of the Institute of Computational Mathematics and Mathematical Geophysics of the Siberian Branch of the Russian Academy of Sciences.

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1038/s41388-018-0608-2

Cite this

@article{9db4fd530ed84471b13224dae03f8616,

title = "Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer",

abstract = "Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.",

author = "Yingqiu Xie and Haiyan Fan and Wenfu Lu and Qing Yang and Ayan Nurkesh and Tleubek Yeleussizov and Aisulu Maipas and Jiang Lu and Limara Manarbek and Zhenbang Chen and Enrico Benassi",

note = "Funding Information: Acknowledgements We would like to thank Drs. Simon W. Hayward and LaMonica Stewart for cell lines, Lynn M. Matrisian for providing MMP7-Luc plasmid. This work was supported in part by NIH grants MD004038, MD007586, CA091408 and CA163069, UL1 RR024975-01 and UL1 TR000445-06. IF and IHC analysis was performed by Meharry Medical College Morphology Core, which is supported in part by NIH grants U54 MD007593, G12 MD007586, R24 DA036420, and S10RR0254970. We would like to thank Dr. Guo-liang Li, Zhanna Alexeyeva, Aigerim Kabulova, Zhibek Keneskha-nova, Akerke Altaikyzy for the kind help or assistant on research. Quantum mechanical calculations were performed on the clusters of the Siberian Supercomputer Center (http://www2.sscc.ru) of the Institute of Computational Mathematics and Mathematical Geophysics of the Siberian Branch of the Russian Academy of Sciences.",

year = "2019",

month = apr,

day = "18",

doi = "10.1038/s41388-018-0608-2",

language = "English",

volume = "38",

pages = "2967--2983",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "16",

}

TY - JOUR

T1 - Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer

AU - Xie, Yingqiu

AU - Fan, Haiyan

AU - Lu, Wenfu

AU - Yang, Qing

AU - Nurkesh, Ayan

AU - Yeleussizov, Tleubek

AU - Maipas, Aisulu

AU - Lu, Jiang

AU - Manarbek, Limara

AU - Chen, Zhenbang

AU - Benassi, Enrico

N1 - Funding Information: Acknowledgements We would like to thank Drs. Simon W. Hayward and LaMonica Stewart for cell lines, Lynn M. Matrisian for providing MMP7-Luc plasmid. This work was supported in part by NIH grants MD004038, MD007586, CA091408 and CA163069, UL1 RR024975-01 and UL1 TR000445-06. IF and IHC analysis was performed by Meharry Medical College Morphology Core, which is supported in part by NIH grants U54 MD007593, G12 MD007586, R24 DA036420, and S10RR0254970. We would like to thank Dr. Guo-liang Li, Zhanna Alexeyeva, Aigerim Kabulova, Zhibek Keneskha-nova, Akerke Altaikyzy for the kind help or assistant on research. Quantum mechanical calculations were performed on the clusters of the Siberian Supercomputer Center (http://www2.sscc.ru) of the Institute of Computational Mathematics and Mathematical Geophysics of the Siberian Branch of the Russian Academy of Sciences.

PY - 2019/4/18

Y1 - 2019/4/18

N2 - Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.

AB - Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.

UR - https://www.scopus.com/pages/publications/85058864169

UR - https://www.scopus.com/pages/publications/85058864169#tab=citedBy

U2 - 10.1038/s41388-018-0608-2

DO - 10.1038/s41388-018-0608-2

M3 - Article

AN - SCOPUS:85058864169

SN - 0950-9232

VL - 38

SP - 2967

EP - 2983

JO - Oncogene

JF - Oncogene

IS - 16

ER -

Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this